CN114651785A - 一种基于PEDF/ApoE双基因敲除的非酒精性脂肪性肝炎小鼠模型构建方法及应用 - Google Patents
一种基于PEDF/ApoE双基因敲除的非酒精性脂肪性肝炎小鼠模型构建方法及应用 Download PDFInfo
- Publication number
- CN114651785A CN114651785A CN202210314234.8A CN202210314234A CN114651785A CN 114651785 A CN114651785 A CN 114651785A CN 202210314234 A CN202210314234 A CN 202210314234A CN 114651785 A CN114651785 A CN 114651785A
- Authority
- CN
- China
- Prior art keywords
- pedf
- alcoholic steatohepatitis
- mouse model
- liver
- mouse
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title claims abstract description 57
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 title claims abstract description 51
- 102100035846 Pigment epithelium-derived factor Human genes 0.000 title claims abstract description 22
- 108090000102 pigment epithelium-derived factor Proteins 0.000 title claims abstract description 22
- 238000010172 mouse model Methods 0.000 title claims abstract description 20
- 102000013918 Apolipoproteins E Human genes 0.000 title claims abstract description 19
- 108010025628 Apolipoproteins E Proteins 0.000 title claims abstract description 19
- 238000003209 gene knockout Methods 0.000 title claims abstract description 15
- 238000010276 construction Methods 0.000 title claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 22
- 229940079593 drug Drugs 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 13
- 208000019425 cirrhosis of liver Diseases 0.000 claims abstract description 11
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 7
- 208000030159 metabolic disease Diseases 0.000 claims abstract description 7
- 238000010171 animal model Methods 0.000 claims description 10
- 208000004930 Fatty Liver Diseases 0.000 claims description 8
- 238000012216 screening Methods 0.000 claims description 8
- 238000013258 ApoE Receptor knockout mouse model Methods 0.000 claims description 7
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 7
- 238000011156 evaluation Methods 0.000 claims description 7
- 238000011813 knockout mouse model Methods 0.000 claims description 7
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 6
- 208000008589 Obesity Diseases 0.000 claims description 5
- 235000020824 obesity Nutrition 0.000 claims description 5
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 4
- 206010022489 Insulin Resistance Diseases 0.000 claims description 4
- 208000010706 fatty liver disease Diseases 0.000 claims description 4
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims description 4
- 201000008980 hyperinsulinism Diseases 0.000 claims description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 239000003596 drug target Substances 0.000 claims description 3
- 230000013011 mating Effects 0.000 claims description 3
- 235000015097 nutrients Nutrition 0.000 claims description 3
- 230000003285 pharmacodynamic effect Effects 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 208000016097 disease of metabolism Diseases 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 abstract description 23
- 206010061218 Inflammation Diseases 0.000 abstract description 12
- 230000004054 inflammatory process Effects 0.000 abstract description 12
- 241000699670 Mus sp. Species 0.000 abstract description 8
- 206010019695 Hepatic neoplasm Diseases 0.000 abstract description 5
- 230000036285 pathological change Effects 0.000 abstract description 3
- 231100000915 pathological change Toxicity 0.000 abstract description 3
- 238000012827 research and development Methods 0.000 abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 31
- 206010028980 Neoplasm Diseases 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 13
- 230000006698 induction Effects 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 10
- 239000008096 xylene Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 239000012188 paraffin wax Substances 0.000 description 8
- 238000010186 staining Methods 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 6
- 210000005228 liver tissue Anatomy 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 4
- 201000001421 hyperglycemia Diseases 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 230000003908 liver function Effects 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 108050006400 Cyclin Proteins 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000010008 shearing Methods 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 206010019668 Hepatic fibrosis Diseases 0.000 description 2
- 206010019837 Hepatocellular injury Diseases 0.000 description 2
- 206010019842 Hepatomegaly Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 231100000437 hepatocellular injury Toxicity 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000007863 steatosis Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 238000013234 NASH mouse model Methods 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- RZUBARUFLYGOGC-MTHOTQAESA-L acid fuchsin Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C1=C(N)C(C)=CC(C(=C\2C=C(C(=[NH2+])C=C/2)S([O-])(=O)=O)\C=2C=C(C(N)=CC=2)S([O-])(=O)=O)=C1 RZUBARUFLYGOGC-MTHOTQAESA-L 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 230000013190 lipid storage Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000001022 morbid obesity Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- XOSXWYQMOYSSKB-LDKJGXKFSA-L water blue Chemical compound CC1=CC(/C(\C(C=C2)=CC=C2NC(C=C2)=CC=C2S([O-])(=O)=O)=C(\C=C2)/C=C/C\2=N\C(C=C2)=CC=C2S([O-])(=O)=O)=CC(S(O)(=O)=O)=C1N.[Na+].[Na+] XOSXWYQMOYSSKB-LDKJGXKFSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/02—Breeding vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Engineering & Computer Science (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
本发明公开了一种基于PEDF/ApoE双基因敲除的非酒精性脂肪性肝炎小鼠模型构建方法及其应用,属于医学技术领域。该模型采用高脂饲料诱导PEDF/ApoE双基因敲除小鼠发生非酒精性脂肪性肝炎表型,该模型构建方法简便,容易推广。利用本发明提供的方法构建的小鼠模型能够较好的模拟人类非酒精性脂肪性肝炎的病变特征,尤其具备极其强烈的肝脏炎症反应和肝脏纤维化表型,并具有一定几率发展为肝脏肿瘤,因此在非酒精性脂肪性肝炎等代谢性疾病的药物研发领域,具有重要的应用前景和价值。
Description
技术领域
本发明属于医学技术领域,尤其涉及一种基于PEDF/ApoE双基因敲除的非酒精性脂肪性肝炎小鼠模型构建方法及应用。
背景技术
非酒精性脂肪肝(Nonalcoholic fatty liver disease,NAFLD)是一种无过量饮酒史,以肝细胞脂肪变性和脂质贮积为特征的临床病理综合征,目前已成为全球慢性肝病的主要病因。其病理变化随病程的进展而表现有单纯性脂肪肝、非酒精性脂肪性肝炎(Nonalcoholic steatohepatitis,NASH)、肝纤维化,并最终发展成肝硬化和肝细胞癌。NASH是非酒精性脂肪肝的一种极端发展形式,定义为伴随有炎症及肝细胞损伤的脂肪变性现象的出现,其特征在于肝脏脂肪变性、炎症、肝细胞损伤和不同程度的纤维化。据统计,目前,NAFLD的全球患病率约为25%,且以每年360万新增病例的速度在急剧增加。其中,约有20%的NAFLD患者进展为NASH,20%的NASH患者进展为肝硬化。因此,NAFLD及NASH发病率的急剧增加已成为全球性的重大公共卫生问题。
NASH病理机制复杂,代谢异常驱动的炎症反应仍被认为是导致NASH发生的关键步骤。然而,尽管关于NASH病理机制研究近年来取得较大进展,但目前尚无经美国食品药品监督管理局(Food and Drug Administration,FDA)批准上市的用于临床治疗NASH的药物,导致NASH患者仍面临“无药可治”的局面。临床前研究中最重要的是通过动物试验测试靶点的合理性和药物的成药性。因此,新药研发成功的关键是选择正确的动物模型。NASH药物临床不断受挫,临床前的动物数据难以转化为临床结果,说明当前的动物模型需要改进。当前的NASH动物模型均不能够同时模拟NASH的发病特征、发病进程及各阶段的病理特征。尤其值得关注的是,当前的NASH动物模型存在一个共性的问题,即炎症反应轻微,难以诱导出严重的肝脏炎症反应。严重的肝脏炎症反应恰恰是NASH区别于单纯性脂肪肝的显著标志,显然,当前的NASH动物模型不利于临床前药物效果的评价。因此,建立一种以严重的肝脏炎症反应为显著特征的NASH小鼠模型对于NASH的药物研发具有重要意义。
发明内容
为了解决上述技术问题,本发明提供一种基于PEDF/ApoE双基因敲除的非酒精性脂肪性肝炎小鼠模型构建方法及应用。
采用本发明提供的构建方法所构建的NASH小鼠模型,表现出肥胖、高血脂、胰岛素抵抗、高血糖、肝脏脂肪变性、肝脏炎症反应、肝脏纤维化和一定程度的肝脏肿瘤发生等人体NASH特征,尤其是具有极其强烈的肝脏炎症反应特征,能够更好的模拟人类NASH的发病特征,为NASH等代谢性疾病药物研发的临床前研究提供了有力的工具。
本发明的目的之一在于提供一种基于PEDF/ApoE双基因敲除的非酒精性脂肪性肝炎小鼠模型的构建方法,其特征在于,包括以下步骤:
(1)利用PEDF敲除小鼠和ApoE敲除小鼠交配获得PEDF/ApoE双基因敲除小鼠;
(2)利用高脂饲料诱导PEDF/ApoE双基因敲除小鼠,获得非酒精性脂肪性肝炎小鼠模型。
进一步的,所述所述的PEDF敲除小鼠与ApoE敲除小鼠均为C57BL/6J背景。
更进一步的,所述步骤(2)中高脂饲料的营养素质量比组成为:蛋白质26.2%、碳水化合物26.3%和脂肪34.9%。
本发明的目的之二在于提供上述非酒精性脂肪性肝炎小鼠模型的构建方法在动物模型构建领域的应用。
本发明的目的之三在于提供利用上述非酒精性脂肪性肝炎小鼠模型的构建方法获得的小鼠模型在筛选预防或治疗代谢性疾病药物中的应用。
进一步的,所述代谢性疾病为肥胖、高血脂、高胰岛素血症、胰岛素抵抗、糖尿病、单纯性脂肪肝、非酒精性脂肪性肝炎及相关的肝纤维化或肝癌中的任一种。
进一步的,所述应用包括药物靶标的筛选、药物的筛选、药物的药效学评价和药物的安全性评价。
与现有技术相比,本发明具有如下有益效果:
本发明采用高脂饲料诱导,符合人类NASH发病特征;表显出肥胖、高血脂、高胰岛素血症、高血糖、肝脏脂肪变性、肝脏炎症反应、肝脏纤维化等NASH表型,并有一定几率发生肝脏肿瘤,尤其是肝脏炎症反应强烈,符合人类NASH病变特征。本发明所述方法简单易行,能广泛推广。由于该模型能够更好的模拟人类NASH的发病特征和病变特征,因此对于NASH等代谢性疾病药物研发的临床前研究提供具有重要意义。
附图说明
图1为实施例1中4组动物在诱导24周后体重、血脂含量、血清胰岛素含量及血糖的检测结果图。
图2为实施例2中4组动物在诱导24周后肝脏重量、肝体比、肝功酶水平、肝脏脂肪变性、肝脏炎症反应及肝脏纤维的检测结果图。
图3为实施例3中4组动物在诱导24周后肝脏肿瘤发生数量以及肿瘤鉴定结果图。
具体实施方式
以下实验用动物及饲养:
PEDF敲除小鼠为C57BL/6J背景,由美国Oklahoma University的马建兴教授课题组构建,并由中山大学中山医学院高国全教授课题组友情赠送。ApoE敲除小鼠为C57BL/6J背景,引进于美国Jackson实验室。PEDF/ApoE双基因敲除小鼠由PEDF敲鼠小鼠和ApoE敲除小鼠交配获得。本发明所用实验动物均在中山大学疾病模式动物中心进行扩繁。
本发明选用实验动物及分组如下:(1)野生正常组:雄性8周龄野生型C57BL/6J小鼠,常规饲料诱导;(2)野生高脂组:雄性8周龄野生型C57BL/6J小鼠,高脂饲料诱导;(3)ApoE敲除高脂组:雄性8周龄ApoE敲除小鼠,高脂饲料诱导;(4)双敲高脂组:雄性8周龄PEDF/ApoE双基因敲除小鼠,高脂饲料诱导。动物于饲养期间自由饮水摄食,每12小时交替照明,温度18-21℃,湿度50%-70%。高脂饲料的营养素质量比组成为:蛋白质26.2%、脂肪34.9%、碳水化合物26.3%。
动物血清及组织取材:
样本收集前,动物禁食不禁水12-16小时。样本收集时,小鼠称重,腹腔注射1%戊巴比妥钠,80mg/kg,待小鼠麻醉后,摘眼球取血并离心收集血清,随后将小鼠仰卧位固定于解剖板上,75%消毒酒精表面消毒,用手术剪剪开小鼠腹腔至胸腔,暴露内脏组织,剪开右心耳,于左心室进针灌注PBS至血液流净,剪下肝脏组织,于PBS中漂洗至无血渍后称重。
病理组织处理:
取小鼠肝脏或肿瘤组织,于PBS中漂洗至无血渍,4%多聚甲醛中固定过夜;PBS洗3次,每次30分钟;25%乙醇、50%乙醇、75%乙醇、90%乙醇、无水乙醇(Ⅰ)、无水乙醇(Ⅱ)梯度脱水,各30分钟;二甲苯(Ⅰ)、二甲苯(Ⅱ)各15分钟;石蜡(Ⅰ)、石蜡(Ⅱ)各60分钟;脱水后,心脏平放于石蜡中包埋;徕卡石蜡切片机切片,片厚5μm。
实施例1
动物的体重、血脂含量、血清胰岛素含量及血糖测定。
上述4组动物在诱导24周时,禁食12-16小时,称重,利用血糖仪测定血糖,并解剖小鼠收集血清样本,利用商业化试剂盒检测血清总胆固醇、甘油三酯和胰岛素含量,结果如图1所示,其中A:体重;B:血清总胆固醇含量;C:血清总甘油三酯含量;D:血清胰岛素含量;F:血糖;**,p<0.01,vs野生正常组;***,p<0.001,vs野生正常组;##,p<0.01,vs野生高脂组;###,p<0.001,vs野生高脂组;&,p<0.05,vsApoE敲除高脂组;&&&,p<0.001,vsApoE敲除高脂组。
非酒精性脂肪性肝炎常伴随肥胖、血脂紊乱、胰岛素抵抗和高血糖,图1结果表明,诱导24周时,相对于其它各组,双敲高脂组小鼠表现出严重的肥胖、脂代谢紊乱、高胰岛素血症和高血糖。
实施例2
上述4组动物在诱导24周时,对动物的肝脏重量、肝体比、肝功酶水平、肝脏脂肪变性、肝脏炎症反应及肝脏纤维化进行评价。
诱导24周时,动物禁食12-16小时后麻醉处死,收集血清和组织样本,并对肝脏组织进行称重;利用商业化试剂盒检测血清谷丙转氨酶和谷草转氨酶水平;并对肝脏组织石蜡切片进行HE染色和Masson染色,以评价肝脏病变情况,结果如图2所示,其中A:肝脏重量;B:肝体比;C:血清谷丙转氨酶水平;D:血清谷草转氨酶水平;E:HE染色;F:CD45免疫组化染色;G:肝脏脂肪变性打分;H:肝脏气球样病变打分;I:肝脏小叶内炎症打分;J:Masson染色;K:肝脏纤维化打分;*,p<0.05,vs野生正常组;**,p<0.01,vs野生正常组;***,p<0.001,vs野生正常组;##,p<0.01,vs野生高脂组;###,p<0.001,vs野生高脂组;&&,p<0.01,vsApoE敲除高脂组;&&&,p<0.001,vs ApoE敲除高脂组。
肝脏石蜡切片HE染色,主要步骤为:60℃烘烤30分钟→二甲苯(Ⅰ)10分钟→二甲苯(Ⅱ)10分钟→无水乙醇(Ⅰ)3分钟→无水乙醇(Ⅱ)3分钟→95%乙醇(Ⅰ)1分钟→70%乙醇1分钟→蒸馏水2分钟→苏木素液5-10分钟→流水洗去苏木素1-3秒钟→1%盐酸酒精1-2秒钟→流水冲洗20分钟→蒸馏水过洗1-2秒钟→0.5%伊红2分钟→蒸馏水稍洗1-2秒钟→95%乙醇(Ⅱ)2-3秒钟→无水乙醇(Ⅲ)3-5秒钟→无水乙醇(Ⅳ)5-10秒钟→二甲苯(Ⅰ)2分钟→二甲苯(Ⅱ)2分钟→中性树胶封片观察。
肝脏石蜡切片Masson染色,主要步骤为:60℃烘烤30分钟→二甲苯(Ⅰ)10分钟→二甲苯(Ⅱ)10分钟→无水乙醇(Ⅰ)3分钟→无水乙醇(Ⅱ)3分钟→95%乙醇(Ⅰ)1分钟→70%乙醇1分钟→蒸馏水2分钟→Weigert氏铁苏木素染5分钟→流水洗去苏木素1-3秒钟→1%盐酸酒精1-2秒钟→流水冲洗20分钟→蒸馏水过洗1-2秒钟→丽春红酸性品红液染5-10分钟→蒸馏水快速漂洗数秒→磷钼酸水溶液处理约3-5分钟→苯胺蓝液复染分钟→1%冰醋酸处理分钟→95%乙醇(Ⅱ)2-3秒钟→无水乙醇(Ⅲ)3-5秒钟→无水乙醇(Ⅳ)5-10秒钟→二甲苯(Ⅰ)2分钟→二甲苯(Ⅱ)2分钟→中性树胶封片观察。
非酒精性脂肪性肝炎常伴随肝脏肿大、肝功酶升高、肝脏脂肪变性、肝细胞气球样病变、肝脏小叶内炎症浸润和肝脏纤维化。图2结果表明,诱导24周时,相对于其它组,双敲高脂组小鼠表现出更严重的肝脏肿大、肝功酶升高、肝脏脂肪变性、肝细胞气球样病变、肝脏小叶内炎症浸润和肝脏纤维化,尤其是肝脏小叶内炎症表现出非常强烈的升高。
实施例3
上述4组动物在诱导24周时,对动物的肝脏肿瘤发生数量进行统计并对肿瘤进行鉴定。
诱导24周时,动物禁食12小时后麻醉处死,收集血清和组织样本,统计各组死亡及发生肝脏肿瘤的小鼠数量,并对发生肿瘤的小鼠及肝脏组织进行大体拍照;对肝脏组织石蜡切片进行HE染色以及AFP、PCNA、CD31的免疫组化染色,以进一步明确肿瘤病变,结果如图3所示,其中A:肿瘤发生数量统计;B:肿瘤小鼠PET/CT结果;C:肿瘤组织(固定后)大体图片;D:肿瘤组织HE染色;E:肿瘤组织AFP染色;F:肿瘤组织PCNA免疫组化;G:肿瘤组织CD31免疫组化。
非酒精性脂肪性肝炎会有部分发展为肝细胞癌,表现出肿瘤部位糖摄取增高、肿瘤组织异常增生、AFP阳性、血管增生等特征。PCNA和CD31分别是细胞增殖和血管标志物,可用来评价细胞增殖和血管增生情况。图3结果表明,诱导24周时,相对于ApoE敲除高脂组,双敲高脂组小鼠表现出更高的肿瘤发生率,肿瘤组织表现出显著的异常增生、AFP阳性以及血管增生等肿瘤特征。
以上所述的实施例仅是对本发明的优选方式进行描述,并非对本发明的范围进行限定,在不脱离本发明设计精神的前提下,本领域普通技术人员对本发明的技术方案做出的各种变形和改进,均应落入本发明权利要求书确定的保护范围内。
Claims (8)
1.一种基于PEDF/ApoE双基因敲除的非酒精性脂肪性肝炎小鼠模型的构建方法,其特征在于,包括以下步骤:
(1)利用PEDF敲除小鼠和ApoE敲除小鼠交配获得PEDF/ApoE双基因敲除小鼠;
(2)利用高脂饲料诱导PEDF/ApoE双基因敲除小鼠,获得非酒精性脂肪性肝炎小鼠模型。
2.根据权利要求1所述的基于PEDF/ApoE双基因敲除的非酒精性脂肪性肝炎小鼠模型的构建方法,其特征在于,所述的PEDF敲除小鼠与ApoE敲除小鼠均为C57BL/6J背景。
3.根据权利要求1或2所述的基于PEDF/ApoE双基因敲除的非酒精性脂肪性肝炎小鼠模型的构建方法,其特征在于,所述步骤(2)中高脂饲料的营养素质量比组成为:蛋白质26.2%、碳水化合物26.3%、脂肪34.9%。
4.如权利要求1-3中任一项所述的非酒精性脂肪性肝炎小鼠模型的构建方法在动物模型构建领域的应用。
5.如权利要求1-3中任一项所述的非酒精性脂肪性肝炎小鼠模型的构建方法获得的小鼠模型在筛选预防或治疗代谢性疾病药物中的应用。
6.如权利要求5所述的应用,其特征在于,所述代谢性疾病为肥胖、高血脂、高胰岛素血症、胰岛素抵抗、糖尿病、单纯性脂肪肝、非酒精性脂肪性肝炎及相关的肝纤维化或肝癌中的任一种。
7.如权利要求5所述的应用,其特征在于,所述应用包括药物靶标的筛选、药物的筛选、药物的药效学评价和药物的安全性评价。
8.如权利要求6所述的应用,其特征在于,所述应用包括药物靶标的筛选、药物的筛选、药物的药效学评价和药物的安全性评价。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210314234.8A CN114651785A (zh) | 2022-03-28 | 2022-03-28 | 一种基于PEDF/ApoE双基因敲除的非酒精性脂肪性肝炎小鼠模型构建方法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210314234.8A CN114651785A (zh) | 2022-03-28 | 2022-03-28 | 一种基于PEDF/ApoE双基因敲除的非酒精性脂肪性肝炎小鼠模型构建方法及应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114651785A true CN114651785A (zh) | 2022-06-24 |
Family
ID=82032856
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210314234.8A Pending CN114651785A (zh) | 2022-03-28 | 2022-03-28 | 一种基于PEDF/ApoE双基因敲除的非酒精性脂肪性肝炎小鼠模型构建方法及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114651785A (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103784973A (zh) * | 2014-01-23 | 2014-05-14 | 武汉大学 | Irf9基因在动脉粥样硬化中的功能及应用 |
CN105052830A (zh) * | 2015-08-04 | 2015-11-18 | 施军平 | 一种基于基因敲除小鼠的脂肪肝相关肝癌模型构建方法 |
CN106491585A (zh) * | 2017-01-06 | 2017-03-15 | 南京市儿童医院 | 鱼藤酮在制备肥胖以及脂肪肝疾病药物中的应用 |
CN107693784A (zh) * | 2017-09-12 | 2018-02-16 | 中山大学 | Pedf基因在治疗糖尿病性心肌损伤中的应用 |
CN107837397A (zh) * | 2017-09-12 | 2018-03-27 | 中山大学 | Pedf基因在治疗急性药物性肝损伤中的应用 |
CN110742020A (zh) * | 2019-09-30 | 2020-02-04 | 中山大学 | 一种高效的高脂血症及动脉粥样硬化小鼠模型及其构建方法 |
-
2022
- 2022-03-28 CN CN202210314234.8A patent/CN114651785A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103784973A (zh) * | 2014-01-23 | 2014-05-14 | 武汉大学 | Irf9基因在动脉粥样硬化中的功能及应用 |
CN105052830A (zh) * | 2015-08-04 | 2015-11-18 | 施军平 | 一种基于基因敲除小鼠的脂肪肝相关肝癌模型构建方法 |
CN106491585A (zh) * | 2017-01-06 | 2017-03-15 | 南京市儿童医院 | 鱼藤酮在制备肥胖以及脂肪肝疾病药物中的应用 |
CN107693784A (zh) * | 2017-09-12 | 2018-02-16 | 中山大学 | Pedf基因在治疗糖尿病性心肌损伤中的应用 |
CN107837397A (zh) * | 2017-09-12 | 2018-03-27 | 中山大学 | Pedf基因在治疗急性药物性肝损伤中的应用 |
CN110742020A (zh) * | 2019-09-30 | 2020-02-04 | 中山大学 | 一种高效的高脂血症及动脉粥样硬化小鼠模型及其构建方法 |
Non-Patent Citations (8)
Title |
---|
南通特洛菲饲料科技有限公司, Retrieved from the Internet <URL:http://www.trophic.cn/profile/high-fat-diet-rodent.html> * |
朱葛丽等: "5-脂氧化酶通路在非酒精性脂肪性肝炎中的作用和机制", 《中国现代医生》, no. 28, 8 October 2016 (2016-10-08) * |
李璐等: "脂肪甘油三酯水解酶的研究进展", 《生物物理学报》 * |
李璐等: "脂肪甘油三酯水解酶的研究进展", 《生物物理学报》, no. 07, 31 July 2012 (2012-07-31) * |
李进鹏等: "高脂饮食对法尼醇受体(FXR)敲除小鼠糖脂代谢及肝脏脂肪变性的影响研究", 《实验动物科学》 * |
李进鹏等: "高脂饮食对法尼醇受体(FXR)敲除小鼠糖脂代谢及肝脏脂肪变性的影响研究", 《实验动物科学》, no. 02, 28 April 2020 (2020-04-28) * |
黄文森等: "色素上皮衍生因子在2型糖尿病合并非酒精性脂肪肝病中的作用", 《中国老年学杂志》 * |
黄文森等: "色素上皮衍生因子在2型糖尿病合并非酒精性脂肪肝病中的作用", 《中国老年学杂志》, no. 04, 25 February 2018 (2018-02-25) * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Musso et al. | Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis | |
KR101761078B1 (ko) | 지방성 간염-간암 모델 동물 | |
Rappa et al. | Immunopositivity for histone macroH2A1 isoforms marks steatosis-associated hepatocellular carcinoma | |
Kurosaki et al. | Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapy | |
Kostrzewski et al. | A microphysiological system for studying nonalcoholic steatohepatitis | |
JP2012080830A (ja) | ヒト非アルコール性脂肪性肝炎(nash)の非ヒトモデル動物 | |
Skelly | The use of imaging to detect schistosomes and diagnose schistosomiasis | |
JP2017006022A (ja) | 非アルコール性脂肪肝炎モデル動物の製造方法 | |
CN103638531A (zh) | Lgr4基因用于筛选促进白色脂肪棕色化的药物 | |
CN114651785A (zh) | 一种基于PEDF/ApoE双基因敲除的非酒精性脂肪性肝炎小鼠模型构建方法及应用 | |
Li et al. | A Bama miniature pig model of monoallelic TSC1 mutation for human tuberous sclerosis complex | |
Zhao et al. | Primary and metastatic squamous cell carcinoma of the thyroid gland: Two case reports | |
Laudenslager et al. | Association between the soluble receptor for advanced glycation end products (sRAGE) and NAFLD in participants in the Atherosclerosis Risk in Communities Study | |
CN114557318B (zh) | 一种基于pedf/ldlr双基因敲除的非酒精性脂肪性肝炎小鼠模型构建方法及应用 | |
CN109730028A (zh) | 一种利用小鼠建立非酒精性脂肪性肝病模型的方法 | |
CN115845058A (zh) | Ctrp6基因在制备预防、治疗或缓解非酒精性脂肪肝病的药物中的应用 | |
JP2009178143A (ja) | 脂肪性肝炎−肝癌モデル動物 | |
CN113398267B (zh) | EphB4作为靶标在筛选增加胰岛素敏感性药物或模型中的应用 | |
Chan et al. | Steatosis drives monocyte-derived macrophage accumulation in human metabolic dysfunction-associated fatty liver disease | |
Song et al. | Thrombospondin1 as a potential therapeutic target for human nonalcoholic fatty liver disease | |
JP6211035B2 (ja) | ヒト非アルコール性脂肪性肝炎(nash)の非ヒトモデル動物 | |
CHU et al. | Inhibition effects of hypoxia on embryonic development and erythropoiesis in zebrafish | |
KR102579433B1 (ko) | 지질 대사 기능 장애 동물 모델로서의 neu2 결손마우스 및 이의 용도 | |
CN108261540A (zh) | Creg在治疗非酒精性脂肪肝和2型糖尿病中的应用 | |
CN114190328A (zh) | 一种基于nlrp3基因敲除的非酒精性脂肪肝动物模型的构建方法及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |